Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May;8(3 Suppl):e18s-23s.
doi: 10.1200/JOP.2012.000541.

Infused chemotherapy use in the elderly after patent expiration

Rena M Conti  1 , Meredith B Rosenthal, Blase N Polite, Peter B Bach, Ya-Chen Tina Shih
Affiliations

Infused chemotherapy use in the elderly after patent expiration

Rena M Conti et al. J Oncol Pract. 2012 May.

Abstract

Purpose: The use of anticancer drugs (chemotherapies) is an important determinant of national spending trends. Recent policies have aimed to accelerate generic entry among chemotherapies to generate cost savings.

Methods: We examined the effects of generic entry on the choice of chemotherapy for the treatment of metastatic colorectal cancer (MCRC) between 2006 and 2009 using autoregressive-moving average modeling with case control. A nationally representative sample of oncologists and patients with cancer (age ≥ 65 years) was employed to estimate the magnitude and significance of the impact of the generic entry of irinotecan in February 2008 on the number of administrations of irinotecan compared with oxaliplatin.

Results: The generic entry of irinotecan resulted in a 17% to 19% decrease (P < .001) in use among elderly patients with MCRC compared with oxaliplatin. The results were robust to multiple sensitivity checks.

Conclusion: This study provides novel and robust estimates of the decline in use of a chemotherapy to treat a common cancer in the elderly after patent expiration. The results suggest estimates from a previous Office of the Inspector General report of the potential savings derived from the generic entry of irinotecan for public payers are an overestimate, likely confounded by oncologists' response to financial incentives, changes in scientific evidence, and promotional activities. As calls for improving the quality and cost efficiency of oncology increase, future empirical work is needed to examine the responsiveness of oncologists' treatment decision making to incentives among patients of all ages and insurance types.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Trends in the number of irinotecan administrations to elderly patients for the treatment of metastatic colorectal cancer from 2007 to 2009.
Fig 2.
Fig 2.
Trends in the number of oxaliplatin administrations to elderly patients for the treatment of metastatic colorectal cancer from 2007 to 2009.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Aitken M, Berndt ER, Cutler DM. Prescription drug spending trends in the United States; looking beyond the turning point. Health Aff (Millwood) 2009;28:w151–w160. - PubMed
    1. Mullins CD, DeVries AR, Hsu VD, et al. Variability and growth in spending for outpatient specialty pharmaceuticals. Health Aff (Millwood) 2005;24:1117–1127. - PubMed
    1. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407–1427. - PubMed
    1. Schrag D. The price tag on progress: Chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317–319. - PubMed
    1. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100:630–641. - PubMed